Home / Biotechnology / Hematopoietic Stem Cells Transplantation Market, By Transplant Type (Allogeneic Transplant, Autologous Transplant), By Application (Leukemia, Lymphoproliferative Disorders, Solid Tumors, Non-Malignant Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Hematopoietic Stem Cells Transplantation Market, By Transplant Type (Allogeneic Transplant, Autologous Transplant), By Application (Leukemia, Lymphoproliferative Disorders, Solid Tumors, Non-Malignant Disorders) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: Jul 2016 | Report Code: 57984-07-16

This report on hematopoietic stem cells transplantation market studies various transplant types and applications. Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

For the purpose of this study, the global hematopoietic stem cells transplantation market on the basis of transplant type is segmented into allogeneic transplant, and autologous transplant. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2022, considering 2015 as the base year.

On the basis of application type global hematopoietic stem cells transplantation market is segmented as leukemia, lymphoproliferative disorders, solid tumors, and non-malignant disorders. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2022, considering 2015 as the base year.

The hematopoietic stem cells transplantation market has been geographically categorized into major regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2013 to 2022 and their CAGRs for the period 2016 to 2022 are provided in this report.

The major key players profiled in the hematopoietic stem cells transplantation market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Kite Pharma Inc., Thermo Fisher Scientific, PromoCell, CellGenix Technologie Transfer GmbH, Cesca Therapeutics Inc.,  R&D Systems, Genlantis, Lonza Group Ltd., TiGenix N.V., and ScienCell Research Laboratories.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hematopoietic Stem Cell Transplantation Market, by Transplantation Type, 2015 v/s 2022 (Value %)
2.2 Global Hematopoietic Stem Cell Transplantation Market, by Application Type, 2015 (USD Mn)
2.3 Global Hematopoietic Stem Cell Transplantation Market, by Geography, 2015 (Value %)

Chapter 3 Global Hematopoietic Stem Cells Transplantation Market Overview
3.1 Overview
3.2 Market Drivers
3.2.1 Increasing Prevalence of Blood Cancer
3.2.2 Better Survival Rates
3.3 Market Restraints
3.3.1 Technical Challenges for Engineering Synthetic HSC Niches at the Nanoscale
3.3.2 Infectious Complications of Hematopoietic Stem Cell Transplantation
3.4 Market Opportunities
3.4.1 Future in Regenerative Stromal Cell Therapy
3.5 Attractive Investment Proposition
3.6 Market Competition Assessment: Hematopoietic Stem Cells, by Key Players

Chapter 4 Global Hematopoietic Stem Cells Transplantation Market Analysis, By Transplant Type
4.1 Overview
4.2 Autologous Transplant
4.3 Allogeneic Transplant

Chapter 5 Global Hematopoietic Stem Cells Transplantation Market Analysis, By Applications
5.1 Overview
5.2 Leukemia
5.3 Lymphoproliferative Disorders
5.4 Solid Tumors
5.5 Non-malignant Disorders

Chapter 6 Global Hematopoietic Stem Cells Transplantion Market, By Geography
6.1 Preface
6.2 North America
6.3 Europe
6.4 Asia Pacific
6.5 Latin America
6.6 Middle East and Africa

Chapter 7 Company Profiles
7.1 Escape Therapeutics
7.1.1 Escape Therapeutics: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.2 Kite Pharma Inc.
7.2.1 Kite Pharma Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.3 PromoCell GmbH
7.3.1 PromoCell GmbH: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.4 ScienCell Research Laboratories
7.4.1 ScienCell Research Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.5 Thermo Fisher Scientific, Inc.
7.5.1 Thermo Fisher Scientific, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.6 CellGenix Technologie Transfer GmbH
7.6.1 CellGenix Technologie Transfer GmbH: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.7 Cesca Therapeutics Inc.
7.7.1 Cesca Therapeutics Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.8 R&D Systems
7.8.1 R&D Systems: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.9 Genlantis
7.9.1 Genlantis: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.10 Lonza Group
7.10.1 Lonza Group: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.11 Pluristem Therapeutics Inc.
7.11.1 Pluristem Therapeutics Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.12 TiGenix N.V.
7.12.1 TiGenix N.V.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.13 Takara Bio
7.13.1 Takara Bio: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
7.14 Stempuetics Research Pvt. Ltd.
7.14.1 Stempuetics Research Pvt. Ltd: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Table :

TABLE 1 Market Competition Assessment: Hematopoietic Stem Cells, by Key Players
TABLE 2 Global Hematopoietic Stem Cells Market, by Transplant Type, 2014-2022 (USD Mn)
TABLE 3 List of Diseases for Autologous HSCT
TABLE 4 Global Hematopoietic Stem Cells Market, by Applications, 2014-2022 (USD Mn)
TABLE 5 Global Hematopoietic Stem Cell Transplants Market, by Geography, 2016 – 2022 (USD Mn)
TABLE 6 Escape Therapeutics: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 7 Kite Pharma Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 8 PromoCell GmbH: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 9 ScienCell Research Laboratories: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 10 Thermo Fisher Scientific, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 11 CellGenix Technologie Transfer GmbH: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 12 Cesca Therapeutics Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 13 R&D Systems: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 14 Genlantis: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 15 Lonza Group: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 16 Pluristem Therapeutics Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 17 TiGenix N.V.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 18 Takara Bio: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
TABLE 19 Stempuetics Research Pvt. Ltd: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)

List Of Figure :

FIG. 1 Hematopoietic Stem Cells Market: Research Methodology
FIG. 2 Global Hematopoietic Stem Cell Transplantation Market, by Transplantation Type, 2015 v/s 2022 (Value %)
FIG. 3 Global Hematopoietic Stem Cell Transplantation Market, by Application Type, 2015 (USD Mn)
FIG. 4 Global Hematopoietic Stem Cell Transplantation Market, by Geography, 2015 (Value %)
FIG. 5 Infection Risk Associated with Type of HSCT
FIG. 6 Attractive Investment Proposition, by Geography, 2015
FIG. 7 Autologous Hematopoietic Stem Cell Transplantation Market, 2014 – 2022 (USD Mn)
FIG. 8 Allogeneic Hematopoietic Stem Cell Transplantation Market, 2014 – 2022 (USD Mn)
FIG. 9 Hematopoietic Stem Cell Transplantation Market in Leukemia, 2014 – 2022 (USD Mn)
FIG. 10 Hematopoietic Stem Cell Transplantation Market for Lymphoproliferative Disorders, 2014 – 2022 (USD Mn)
FIG. 11 Hematopoietic Stem Cell Transplantation Market for Solid Tumors, 2014 – 2022 (USD Mn)
FIG. 12 Hematopoietic Stem Cell Transplantation Market for Non-malignant Disorders, 2014 – 2022 (USD Mn)
FIG. 13 North America Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (US$ Mn)
FIG. 14 Europe Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (US$ Mn)
FIG. 15 Asia-Pacific Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (US$ Mn)
FIG. 16 Latin America Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (US$ Mn)
FIG. 17 Middle East and Africa Hematopoietic Stem Cell Transplant Market , 2013 – 2022 (US$ Mn)

Based on the type of application, the hematopoietic stem cells transplantation market is segmented into:

  • Leukemia
  • Lymphoproliferative Disorders
  • Solid Tumors
  • Non-malignant Disorders

Hematopoietic stem cell transplantation is defined as intravenous infusion of hematopoietic stem and progenitor cells for the purpose of establishing immune and marrow functions in patients with variety of inherited and acquired malignancies and non-malignancies. Hematologic malignancies such as leukemia, lymphoma and myeloma and non-malignant conditions such as bone marrow disorders (aplastic anemia) and genetic diseases concerned with abnormal hematopoiesis and function such as sickle cell anemia, thalassemia, and combined immunodeficiency. In 2015, lymphoproliferative disorders and leukemia accounted for more than 50% of the market share. According to cancer research UK, leukemia is the 11th most common cancer worldwide which represented 2% of total cancer cases. Its incidence rates are the highest in Australia and New Zealand and the least in West Africa. In 2016, 60,140 individuals are expected to be diagnosed with leukemia and an estimated 345,422 people were living with leukemia in the U.S. As the prevalence of leukemia is anticipated to continue to grow, it is expected that that demand for more effective treatment options will further augment. The major conditions in lymphoproliferative disorders that use HSCT as a viable treatment option are plasma cell disorders, Hodgkin’s disease, non-Hodgkin lymphoma, and other lymphomas. HSCT is frequently considered for treating patients with non-Hodgkin lymphoma (NHL). Autologous transplant is preferred for patients with relapsed non-Hodgkin lymphoma or the patients in first remission. NHL patients are recommended allogeneic HSCT due to the high rate of relapse observed after chemotherapy and autologous HSCT. Allogeneic HSCT in indolent lymphoproliferative disorders allow graft versus leukemia effect and thus the risk of graft contamination by residual tumor cells is kept at bay.

Hematopoietic Stem Cells Transplantation Market

Based on the type of transplant, the global hematopoietic stem cells transplantation market is segmented as follows:

  • Autologous Transplant
  • Allogeneic Transplant

Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The scope of HSCT procedure is anticipated to expand through the future decades. The list of indications for both allogeneic and autologous HSCT of both malignant and non-malignant blood disorders will continue to grow. Other life-threatening conditions such as metabolic diseases, autoimmune conditions, and genetic diseases will be further scrutinized for HSCT treatment. The last few decades have fetched improvement in the survival rates of the patients diagnosed with conditions such as multiple myeloma. Several factors such as better supportive care, access to hematopoietic progenitor cell transplant and availability of breakthrough drugs contribute to the longevity of patients suffering from malignant and non-malignant blood disorders. Autologous HSCT has been preferred over allogeneic HSCT due to absence of risk of graft versus host disease.

Hematopoietic Stem Cells Transplantation Market

For the purpose of this study, the global hematopoietic stem cells transplantation market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

Hematopoietic Stem Cells Transplantation Market

In base year 2015, North America was observed as the largest and most potential regional market for hematopoietic stem cells transplantation. North America constitutes regional markets of U.S. and Canada, the rising prevalence of cancers and anemia is the major driver for the growth of global hematopoietic stem cell transplant market. The developed healthcare infrastructure, high public awareness related to stem cell transplant, and rising prevalence awareness related to cancer and rare diseases are the key factors assisting the growth of North America hematopoietic stem cell transplantation market. Asia Pacific is the expected to be the most potential regional market for hematopoietic stem cell transplants market by 2022. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. Numerous factors such as developing economical landscape and industrialization, increasing disposable incomes, growing public awareness related to stem cell therapy, and increasing government support through providing favorable environments for stem cell research laboratories are the major factors expected to assist the growth of Asia Pacific market.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients